

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs ^{66.4 kg} 146 pounds. What size needle will you use?
1-inch, 23 gauge
2. Name the most common side effects a patient may experience when taking Invega Sustenna®.
Injection site reactions, sleepiness or drowsiness, dizziness, feeling restless or needing to constantly be moving, abnormal muscle movements including tremor, shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes
3. What black box warning is associated with this medication?
Increased risk of death in elderly people with dementia-related psychosis
4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?
Day 1 = 234 mg Day 8 = 156 mg
5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?
39 - 234 mg
6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?
The deltoid
7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65 mL/min?
Day 1 = 156 mg Day 8 = 117 mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

78mg

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

To establish a tolerability

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

Hold syringe upright to remove rubber tip cap. Peel the pouch half-way open and use pouch to attach the needle to the luer connection. Pull the needle sheath away from needle with a straight pull - never twist.

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

so that the patient understands why they are receiving the medication, what it will do to them, and possible side effects to watch for.